home
Dalla valorizzazione economica e scientifica del brevetto EP3458607, nasce EMIL, un nuovo avanzato prototipo di diagnosi e prognosi veloce, di facile utilizzo, affidabile, efficace ed economico per i pazienti con Leucemia Promielocitica Acuta (LPA).
EMIL è in grado di determinare una signature epigenetica correlata alla resistenza alla terapia standard e/o alla Low Overall Survival in pazienti LPA.
Epi-C’s goal is to modulate the complex mechanism of epigenetic regulation, forcing cancer cells to restore physiological activity and die either for senescence or programmed death – apoptosis .
In addition, since epigenetic mechanism(s) modulate both the induction and the interference with cell death, Epi-C’s molecules might be applied to degenerative diseases, as well as chronic, metabolic alterations.
Epi-C is a Drug-Agent
specialized in the discovery phase of new molecules
Epi-C (Epigenetic Compounds) is a new spin-off biotech company operating in the field of epigenetics. One of our primary aims is to develop novel drugs with anti-cancer properties.
Epi-C performs small molecule screenings, as well as bio logical and molecular characterisation of drugs.
Epi-C workflow
Epi-C workflow based on library high-throughput screening (HTS)
by automated equipment, data analysis, processing, Hit to lead Identification and Optimization.
Top Italian Scientists (TIS)
EpiGenetics Medicine
Lucia Altucci
MD, PhD
Full Professor of General Pathology, University of Campania Luigi Vanvitelli, IT. She is the scientific director of Epi-C and has more than 20 years of experience and more than 170 scientific publications on epigenetics to his credit.
SOME NUMBERS
DRUG SCREENING
High-throughput screen
of a large compound collection.
DRUG TESTING
Drug testing efficacy, reproducibility and specificity: 90-100%.
DRUG DISCOVERY
Hit identification success
80% during years.
PATENT OF DISCOVERED
Patent of Discovered
Lead compounds: 100%
Anticancer Research
JMJ KIT - KDM4A
Inhibitor Enzymatic
Assay Kit
EPI-C TIMELINE
PARTNERS
